Top Duchenne Muscular Dystrophy Research Leaders (KOLs) 2021-2026

Top research leaders (by recent publication volume)

#	Researcher	Affiliation	Papers
1	Yokota Toshifumi	University of Alberta	36
2	Aoki Yoshitsugu	National Institute of Neuroscience	15
3	Aartsma-Rus Annemieke	Leiden University Medical Center	14
4	Muntoni Francesco	University College London	9
5	Maruyama Rika	University of Alberta	8
6	Wein Nicolas	Nationwide Children's Hospital	7
7	Garcia Luis	Université Paris-Saclay	6
8	Takeda Shin'ichi	National Institute of Neuroscience	6
9	Mercuri Eugenio	Catholic University	6
10	Servais Laurent	University of Oxford	6
11	Goyenvalle Aurélie	Université Paris-Saclay	5
12	Shah Md Nur Ahad	University of Alberta	5
13	Echigoya Yusuke	College of Bioresource Sciences	5
14	Hotta Akitsu	Kyoto University	4
15	Motohashi Norio	National Institute of Neuroscience	4
16	Lu-Nguyen Ngoc	Royal Holloway University of London	4
17	Malerba Alberto	Royal Holloway University of London	4
18	Popplewell Linda	Royal Holloway University of London	4

Ranked by recent publication volume; names not yet disambiguated and not citation-weighted. The full brief adds ORCID disambiguation, citation weighting, and clinical-trial investigator data.

Leading institutions

University of Alberta (30), National Institute of Neuroscience (16), Leiden University Medical Center (15), Nationwide Children's Hospital (13), Sarepta Therapeutics (13), University of Oxford (10), Université Paris-Saclay (8), University of Alberta Faculty of Medicine and Dentistry (7), Sorbonne Université (5), National Center Hospital (5)

Active subtopics

Muscular Dystrophy, Duchenne (180), Dystrophin (145), Exons (115), Genetic Therapy (94), Oligonucleotides, Antisense (83), Mice (60), Disease Models, Animal (44), Morpholinos (40), Muscle, Skeletal (39), Mice, Inbred mdx (39), Mutation (27)

Top journals

Methods in molecular biology (Clifton, N.J.) (26), Journal of neuromuscular diseases (18), International journal of molecular sciences (9), Molecular therapy. Nucleic acids (8), Nucleic acid therapeutics (8), Human gene therapy (7)

Representative recent papers

Rewriting Duchenne muscular dystrophy therapy. (2026) · PMID 42425062

RNA Therapeutics Targeting Skeletal Muscle: Emerging Antisense and Gene-Modifying Strategies. (2026) · PMID 42352260

FDA-approved antisense oligonucleotide therapies for duchenne muscular dystrophy: current status and future outlook. (2026) · PMID 42324661

Long-term reversal of Duchenne muscular dystrophy via circular arRNA-guided exon skipping in monkeys and humans. (2026) · PMID 42269605

U7snRNA-mediated skipping of intron-derived pseudoexons restores full-length (2026) · PMID 42232222

Want the full cited brief?

A full Duchenne Muscular Dystrophy brief adds citation weighting, name disambiguation, clinical-trial investigators, and a cited PDF, scoped to your exact molecule, competitor set, or region.

Try the live tool Contact us